Table 4 Changes of regional myocardial function (VM202 injected area)

From: Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study

Modality Parameter Months after VM202 treatment Measurement P-valuea Adjusted P-valuea
    Mean±s.d. Median (range)   
Myocardial SPECT Stress perfusion (%) Baseline 58.3±10.2 60.0 (41.569.5) 0.0031
   3 64.3±9.6 69.0 (51.074.5)   0.024
   6 63.9±9.7 68.0 (47.576.5)   0.024
  Rest perfusion (%) Baseline 70.2±8.6 72.5 (51.081.0) 0.0705
   3 74.5±7.5 74.5 (61.084.5)  
   6 72.2±7.9 72.0 (61.589.5)  
  Systolic thickening (%) Baseline 33.4±22.8 42.5 (0.070.5) 0.7479
   3 32.4±11.3 35.5 (17.055.5)  
   6 34.2±14.5 36.0 (12.051.0)  
Cardiac MRI Systolic wall thickness (mm) Baseline 10.3±2.8 10.0 (6.515.0) 0.0650
   3 10.8±2.6 11.0 (6.115.3)  
   6 11.0±2.4 11.5 (6.313.9)  
  Diastolic wall thickness (mm) Baseline 7.0±1.0 7.0 (5.58.7) 0.0731
   3 7.5±1.2 7.7 (5.49.2)  
   6 7.5±1.1 7.8 (5.19.0)  
  Systolic thickening (%) Baseline 46.1±26.6 43.0 (15.089.0) 0.6544
   3 42.8±22.7 53.0 (12.068.0)  
   6 46.6±17.4 55.0 (19.064.0)  
  1. Abbreviations: MRI, magnetic resonance imaging; SPECT, single photon emission computed tomography.
  2. aDifferences in the response variable among the three period were compared with nonparametric RMANOVA. Multiple pair-wise comparisons were made with Hochberg’s procedure, with the overall alpha level at 0.05., s.d., standard deviation.